To assess the efficacy, safety, and pharmacokinetics (PK) of oral lubiprostone 12 or 24 mcg capsules dosed twice daily (BID) (based on subject body weight at baseline) as compared to matching placebo BID, when administered orally for 12 weeks in pediatric subjects with functional constipation.